Tirzepatide + Tirzepatide Placebo

ApprovedRecruiting
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Idiopathic Intracranial Hypertension (IIH)

Conditions

Idiopathic Intracranial Hypertension (IIH)

Trial Timeline

Feb 1, 2026 โ†’ Feb 1, 2028

About Tirzepatide + Tirzepatide Placebo

Tirzepatide + Tirzepatide Placebo is a approved stage product being developed by Eli Lilly for Idiopathic Intracranial Hypertension (IIH). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07191873. Target conditions include Idiopathic Intracranial Hypertension (IIH).

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT07191873ApprovedRecruiting

Competing Products

20 competing products in Idiopathic Intracranial Hypertension (IIH)

See all competitors